Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test.

[1]  Clare Gilham,et al.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials , 2014, The Lancet.

[2]  Practice Bulletin No. 140: Management of Abnormal Cervical Cancer Screening Test Results and Cervical Cancer Precursors , 2013, Obstetrics and gynecology.

[3]  Robert P Berkowitz,et al.  2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. , 2013, Obstetrics and gynecology.

[4]  J. T. Cox,et al.  Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. , 2013, American journal of obstetrics and gynecology.

[5]  Julian Peto,et al.  Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. , 2012, Vaccine.

[6]  V. Moyer,et al.  Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[7]  M. Schiffman,et al.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer , 2012 .

[8]  J. Berkhof,et al.  HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications , 2012, British Journal of Cancer.

[9]  Jennifer S Lin,et al.  Liquid-Based Cytology and Human Papillomavirus Testing to Screen for Cervical Cancer: A Systematic Review for the U.S. Preventive Services Task Force , 2011, Annals of Internal Medicine.

[10]  T. Wright,et al.  Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. , 2011, American journal of clinical pathology.

[11]  Thomas C Wright,et al.  Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. , 2011, The Lancet. Oncology.

[12]  Mark Schiffman,et al.  Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. , 2011, The Lancet. Oncology.

[13]  David R. Scott,et al.  A Long-term Prospective Study of Type-Specific Human Papillomavirus Infection and Risk of Cervical Neoplasia Among 20,000 Women in the Portland Kaiser Cohort Study , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[14]  J. Peto,et al.  A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. , 2011, European journal of cancer.

[15]  S. Wacholder,et al.  Human papillomavirus testing in the prevention of cervical cancer. , 2011, Journal of the National Cancer Institute.

[16]  Yifei Ma,et al.  Rate of and Risks for Regression of Cervical Intraepithelial Neoplasia 2 in Adolescents and Young Women , 2010, Obstetrics and gynecology.

[17]  N. Segnan,et al.  European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition—Summary Document , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  J. Cuzick,et al.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. , 2010, The Lancet. Oncology.

[19]  A. Anttila,et al.  Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. , 2009, Journal of the National Cancer Institute.

[20]  C. Wheeler,et al.  Evidence for Frequent Regression of Cervical Intraepithelial Neoplasia–Grade 2 , 2009, Obstetrics and gynecology.

[21]  Joakim Dillner,et al.  Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study , 2008, BMJ : British Medical Journal.

[22]  J. Cuzick,et al.  Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. , 2006, The Lancet. Oncology.

[23]  J. Cuzick,et al.  Benefit of cervical screening at different ages: evidence from the UK audit of screening histories , 2003, British Journal of Cancer.

[24]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[25]  M. van Ballegooijen,et al.  Cervical cancer screening in the Netherlands. , 2000, European journal of cancer.

[26]  D. Slater,et al.  National cervical screening programme. , 1990, BMJ.

[27]  ACOG Practice Bulletin Number 131: Screening for cervical cancer. , 2012, Obstetrics and gynecology.

[28]  Thomas C Wright,et al.  The ATHENA human papillomavirus study: design, methods, and baseline results. , 2012, American journal of obstetrics and gynecology.

[29]  N. MiahMd,et al.  Women's health care. , 1988 .